Gastric Cancer Clinical Trials

283 recruiting

Gastric Cancer Trials at a Glance

420 actively recruiting trials for gastric cancer are listed on ClinicalTrialsFinder across 6 cities in 51 countries. The largest study group is Phase 2 with 131 trials, with the heaviest enrollment activity in Seoul, Shanghai, and New York. Lead sponsors running gastric cancer studies include Fudan University, AstraZeneca, and National Cancer Institute (NCI).

Browse gastric cancer trials by phase

Treatments under study

About Gastric Cancer Clinical Trials

Looking for clinical trials for Gastric Cancer? There are currently 283 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Gastric Cancer trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Gastric Cancer clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 420 trials

Recruiting

Surgery in Gastrointestinal Stromal Tumors (GISTs) for Treatment, Tumor Modeling, and Genomic Analysis

Gastric CancerGastric NeoplasmGastrointestinal Stromal Tumor (GIST)+2 more
National Cancer Institute (NCI)400 enrolled1 locationNCT04557969
Recruiting
Phase 2Phase 3

Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial

Clinical Stage III Gastric Cancer AJCC v8Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8Clinical Stage IV Gastric Cancer AJCC v8+13 more
National Cancer Institute (NCI)224 enrolled370 locationsNCT06203600
Recruiting
Phase 1Phase 2

Lead-212 PSV359 Therapy for Patients With Solid Tumors

Esophageal CancerGastric CancerPancreatic Ductal Adenocarcinoma
Perspective Therapeutics112 enrolled7 locationsNCT06710756
Recruiting

Tumor Cell and DNA Detection in the Blood, Urine and Bone Marrow of Patients With Solid Cancers

Esophageal CancerPancreatic CancerGastric Cancer+2 more
University of Missouri-Columbia620 enrolled1 locationNCT02838836
Recruiting
Phase 1

A Phase 1, Dose-escalation Study of [225Ac]-FPI-2068 in Adult Patients With Advanced Solid Tumours

Gastric CancerAdvanced Solid TumorNon-small Cell Lung Cancer+4 more
AstraZeneca70 enrolled15 locationsNCT06147037
Recruiting
Phase 1Phase 2

Study of Anti-CEACAM5 ADC M9140 in Participants With Advanced Solid Tumors (PROCEADE PanTumor)

Gastric CancerSolid Tumors
EMD Serono Research & Development Institute, Inc.250 enrolled81 locationsNCT06710132
Recruiting
Not Applicable

Comparison of Partial Stomach-Partitioning and Conventional Gastrojejunostomy for the Treatment of Gastric Outlet Obstruction in Advanced Gastric Cancer

Gastric Cancer
Guangxi Medical University80 enrolled1 locationNCT07561073
Recruiting
Phase 2

LM-302 and S-1 Plus Intraperitoneal Paclitaxel With or Without Cadonilimab for Claudin 18.2-positive Gastric or Gastroesophageal Junction Adenocarcinoma With Peritoneal Metastasis: a Prospective, Exploratory Study

Peritoneal Metastases From Gastric CancerGastric Cancer Stage IVGastric or Esophagogastric Junction Adenocarcinoma
Ruijin Hospital74 enrolled1 locationNCT07556640
Recruiting
Phase 2

18F-Fibroblast Activation Protein Inhibitor ([18F]FAPI-74) PET Imaging for Cancer Detection

Gastric CancerOvarian CancerCholangiocarcinoma+7 more
National Cancer Institute (NCI)320 enrolled1 locationNCT06503146
Recruiting
Phase 1Phase 2

Administering Peripheral Blood Lymphocytes Transduced With a Murine T-Cell Receptor Recognizing the G12V Variant of Mutated RAS in HLA-A*11:01 Patients

Pancreatic CancerGastric CancerColon Cancer+2 more
National Cancer Institute (NCI)110 enrolled1 locationNCT03190941
Recruiting
Phase 2

Study Evaluating the Efficacy of the myDIET Software Tool in the Nutritional Management of Patients With Localized and Resectable Gastric or Esogastric Junction Cancer.

Gastric CancerOesogastric Junction Cancer
Centre Leon Berard60 enrolled1 locationNCT06385691
Recruiting
Not Applicable

Proximal Gastrectomy vs Total Gastrectomy in Locally Advanced Upper Gastric Cancer After Neoadjuvant Therapy

Locally Advanced Gastric Cancer
Guihua Wang404 enrolled1 locationNCT06597227
Recruiting
Phase 1Phase 2

Study for AZD4360 in Participants With Advanced Solid Tumours

Gastric Cancer
AstraZeneca117 enrolled18 locationsNCT06921928
Recruiting

AI Model for Early Gastric Cancer Diagnosis Using Endoscopic Imaging

Early Gastric Cancer
The First Affiliated Hospital of Soochow University100 enrolled1 locationNCT07551466
Recruiting
Phase 1

CA-4948 in Combination With FOLFOX/PD-1 Inhibitor +/- Trastuzumab for Untreated Unresectable Gastric and Esophageal Cancer

Esophageal CancerGastric CancerEsophagus Cancer+1 more
Washington University School of Medicine42 enrolled1 locationNCT05187182
Recruiting
Phase 1

A Study to Examine the Safety of Different Doses of BG-68501 Given to Participants With Advanced-Stage Tumors

Breast CancerGastric CancerOvarian Cancer+1 more
BeiGene258 enrolled24 locationsNCT06257264
Recruiting

Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line Treatment of G/GEJ Adenocarcinoma

Gastric Cancer
Cancer Institute and Hospital, Chinese Academy of Medical Sciences60 enrolled1 locationNCT06417892
Recruiting

ctDNA-MRD Monitoring After Resection in Gastric Cancer

Gastric Cancer
Peking University110 enrolled1 locationNCT06893133
Recruiting

A Long-term Follow-up Study of Subjects Enrolled in Clinical Trials of Cadonilimab (AK104)

Locally Advanced Unresectable or Metastatic Gastric Cancer
Akeso610 enrolled1 locationNCT07547787
Recruiting

Immediate and Functional Results of Different Types of Reconstructions After Proximal Gastrectomy For Gastric and Esophagogastric Junction Cancer

Gastric Cancer (GC)Siewert Type III Adenocarcinoma of Esophagogastric JunctionSiewert Type II Adenocarcinoma of Esophagogastric Junction
P. Herzen Moscow Oncology Research Institute400 enrolled1 locationNCT07441785